세계의 HCS(High Content Screening) 시장 : 제품 및 서비스별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)
High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030
상품코드:1697828
리서치사:MarketsandMarkets
발행일:2025년 04월
페이지 정보:영문 358 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 HCS(High Content Screening) 시장 규모는 2025년 15억 2,000만 달러에서 2030년 21억 9,000만 달러에 달할 것으로 예상되며, 연평균 7.5%의 높은 성장률을 나타낼 것으로 예상됩니다.
이 시장은 고해상도 이미징, 자동화, 인공지능(AI)을 활용한 데이터 분석의 혁신으로 인해 HCS 워크플로우의 효율성과 정확성이 크게 향상됨에 따라 연평균 성장률(CAGR)이 크게 증가하고 있습니다. 고속 형광 현미경, 공초점 이미징, 실시간 라이브 셀 분석 기능을 갖춘 첨단 장비는 더 깊은 세포 통찰력을 제공하여 신약 개발, 독성 스크리닝, 질병 연구에 필수적인 요소로 자리 잡고 있습니다.
조사 범위
조사 대상 연도
2023-2030년
기준 연도
2024년
예측 기간
2025-2030년
검토 단위
금액(USD)
부문별
제품/서비스별, 용도별, 최종사용자별, 지역별
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카
제품 및 서비스별로 HCS(High Content Screening) 시장은 장비, 소모품 및 액세서리, 소프트웨어, 서비스로 구분됩니다. 장비 부문은 다시 고함량 이미징 플랫폼, 세포 검출 및 분석 시스템, 세포 이미징 시스템으로 세분화됩니다. 제약 및 생명공학 연구 분야에서 하이스루풋 스크리닝 및 멀티플렉스 분석에 대한 수요가 증가함에 따라 차세대 HCS 시스템의 도입이 가속화되고 있습니다. 연구기관 및 상업용 연구소가 생산성과 효율성 향상을 목표로 하는 가운데, 최첨단 HCS 장비에 대한 수요가 시장의 큰 성장을 견인할 것으로 예상됩니다.
용도별 부문은 신약개발, 독성학, 기초연구로 나뉩니다. 신약개발 응용 분야는 다시 1차 스크리닝 및 2차 스크리닝, 표적 식별 및 검증, 화합물 프로파일링, 기타 신약개발 응용 분야로 나뉩니다. 신약개발은 신약개발 워크플로우에서 인공지능과 자동화의 통합이 HCS의 효율성을 더욱 높이고 전임상 연구와 관련된 시간과 비용을 절감할 수 있기 때문에 신약개발이 시장을 주도하고 있습니다. 또한, 규제 기관은 초기 독성 평가를 중요시하기 때문에 HCS는 임상시험 전 의약품 안전성 평가에 선택되고 있습니다. 이러한 요인들이 결합되어 HCS 시장에서 신약 개발 용도가 압도적인 점유율을 차지하고 있습니다.
최종 사용자별로 시장은 제약 및 생명공학 기업, 학술 및 정부 기관, CRO 및 CDMO로 구분되며, 2024년에는 제약 및 생명공학 기업이 이 부문을 지배할 것으로 예상됩니다. HCS(High Content Screening)(HCS) 시장에서 제약 및 생명공학 기업의 높은 점유율은 주로 신약 개발 및 시장 개척에 HCS 기술을 광범위하게 활용하고 있기 때문입니다. 이들 기업들은 HCS를 활용하여 의약품 개발 프로세스를 가속화하면서 안전성과 효능을 보장하기 위해 고처리량 스크리닝, 리드 화합물 최적화, 독성 평가에 활용하고 있습니다.
지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 북미는 2024년 HCS(High Content Screening) 시장을 장악할 것으로 예상되며, 예측 기간 동안 계속 지배할 것으로 예상됩니다. 미국은 주요 학술 연구 기관의 존재와 생명공학에 대한 막대한 투자로 인해 북미 시장을 주도하고 있습니다. 미국은 혁신적인 의학 연구, 개인 맞춤형 의료, 정밀의료에 집중하고 있으며, 이는 이 시장에서 미국의 리더십을 더욱 강화할 것으로 예상됩니다. 유럽의 HCS(High Content Screening) 시장은 특히 독일, 영국, 프랑스와 같은 국가들의 R&D 활동 증가에 힘입어 꾸준한 성장세를 보이고 있습니다.
세계의 HCS(High Content Screening) 시장에 대해 조사했으며, 제품 및 서비스별/용도별/최종사용자별/지역별 동향, 시장 진출 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
서론
시장 역학
고객의 비즈니스에 영향을 미치는 동향/혼란
가격 분석
공급망 분석
밸류체인 분석
생태계 분석
AI/생성형 AI의 영향
기술 분석
특허 분석
2025-2026년 주요 컨퍼런스 및 이벤트
규제 상황
Porter의 Five Forces 분석
주요 이해관계자와 구입 기준
투자와 자금조달 시나리오
제6장 HCS(High Content Screening) 시장, 제품 및 서비스별, 2022년-2029년(100만 달러)
The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%. The market is growing at a significant CAGR owing to the innovations in high-resolution imaging, automation, and artificial intelligence (AI)-powered data analysis, which have significantly enhanced the efficiency and accuracy of HCS workflows. Advanced instruments equipped with high-speed fluorescence microscopy, confocal imaging, and real-time live-cell analysis enable deeper cellular insights, making them essential for drug discovery, toxicity screening, and disease research.
Scope of the Report
Years Considered for the Study
2023-2030
Base Year
2024
Forecast Period
2025-2030
Units Considered
Value (USD)
Segments
By Products & Service, Application and End User
Regions covered
North America, Europe, Asia Pacific, Latin America, Middle East and Africa
"Instruments dominated the products & service segment"
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
"Drug discovery & development application segment is anticipated to grow at a great pace"
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
"Pharmaceutical & Biotechnology Companies dominated the segment"
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
"North America: the largest share of the high content screening market"
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country's focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the high content screening market.
The primary interviews conducted for this report can be categorized as follows:
By Respondent: Tire 1- 55%, Tire 2-25%, Tire 3- 20%
By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Corning Incorporated (US), Bio-Rad Laboratories Inc (US), Tecan Trading AG (Switzerland), Evident (Japan), Sysmex Corporation (Japan), Yokogawa Electric Corporation (Japan), Nikon Corporation (Japan), Sartorius AG (Germany), Promega Corporation (US), Creative Biolabs (US), Enzo Life Sciences (US), Stratedigm Inc. (US), Akoya Biosciences, Inc. (US), Sphere Fluidics (UK), Creative Biostructure (US), Creative Bioarray (US), Cell Signalling Technology (US), Standard Biotools (US), Araceli Biosciences (US), and among others.
Research Coverage:
High content screening market report is segmented based on products & services (instruments (high content imaging platforms, cell detection and analysis systems, and cell imaging systems), consumables & accessories (reagents & assay kits, microplates, and other consumables accessories), software, and services. Applications (drug discovery & development applications (primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications), toxicology, and basic research, end users (pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
Analysis of key drivers (Advancements in Imaging Technologies, Increased R&D projects, Adoption of High Throughput Screening, implementing organoid models in HCS), restraints (High Equipment and Reagents Costs, Complexity of Data Analysis), opportunities (Integration of AI and ML, Expansion into new applications) and Challenges (Lack of Standardized Protocol) influencing the growth of the market.
Product Development/Innovation: Detailed insights on upcoming technologies in high content screening, research and development activities, and new product launches in the high content screening market.
Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the high content screening market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.7.1 IMPACT OF AI/GENERATIVE AI
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF AI/GEN AI
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.3 ADJACENT TECHNOLOGIES
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS 2025-2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTE
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITION RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA FOR END USERS
5.15 INVESTMENT AND FUNDING SCENARIO
6 HIGH CONTENT SCREENING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
6.1 INTRODUCTION
6.2 INSTRUMENTS
6.2.1 CELL IMAGING SYSTEMS
6.2.2 CELL DETECTION AND ANALYSIS SYSTEMS
6.2.3 HIGH CONTENT IMAGING PLATFORMS
6.3 CONSUMABLES & ACCESSORIES
6.3.1 REAGENTS & ASSAY KITS
6.3.2 MICROPLATES
6.3.3 OTHER CONSUMABLES & ACCESSORIES
6.4 SOFTWARE
6.5 SERVICES Note 1: Other consumables & accessories segment is inclusive of cell culture accessories, microscopy accessories, and plate sealers. Note 2: The above product & service segmentation is subject to change during research.
7 HIGH CONTENT SCREENING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
7.1 INTRODUCTION
7.2 DRUG DISCOVERY AND DEVELOPMENT
7.2.1 TARGET IDENTIFICATION AND VALIDATION
7.2.2 PRIMARY SCREENING AND SECONDARY SCREENING
7.2.3 COMPOUND PROFILING
7.2.4 OTHER DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS (IF ANY)
7.2 TOXICOLOGY
7.3 BASIC RESEARCH Note 3: Basic research application segment is inclusive of cancer cell line screening, epigenetics, gene expression analysis, and stem cell research.
8 HIGH CONTENT SCREENING MARKET, BY END USER, 2022-2029 (USD MILLION)
8.1 INTRODUCTION
8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
8.3 ACADEMIC AND GOVERNMENT INSTITUTES
8.4 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
9 HIGH CONTENT SCREENING MARKET, BY REGION, 2022-2029 (USD MILLION)
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.3 CANADA
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 GERMANY
9.3.3 UK
9.3.4 FRANCE
9.3.5 ITALY
9.3.6 SPAIN
9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 JAPAN
9.4.3 CHINA
9.4.4 INDIA
9.4.5 SOUTH KOREA
9.4.6 AUSTRALIA
9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
9.6 MIDDLE EAST
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
9.6.2 GCC COUNTRIES 9.6.2.1 UNITED ARAB EMIRATES (UAE) 9.6.2.2 KINGDOM OF SAUDI ARABIA (KSA) 9.6.2.3 REST OF GCC COUNTRIES
12.6.3 REST OF MIDDLE EAST
9.7 AFRICA
9.7.1 MACROECONOMIC OUTLOOK FOR AFRICA
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
10.3 REVENUE SHARE ANALYSIS (TOP 4-5 PLAYERS)
10.4 MARKET SHARE ANALYSIS (TOP 4-5 PLAYERS)
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS
10.5.5.1 COMPANY FOOTPRINT
10.5.5.2 PRODUCT FOOTPRINT
10.5.5.3 SERVICE FOOTPRINT
10.5.5.4 APPLICATION FOOTPRINT
10.5.5.5 REGION FOOTPRINT
10.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
